111 related articles for article (PubMed ID: 29103025)
1. Integrated analysis reveals down-regulation of SPARCL1 is correlated with cervical cancer development and progression.
Wu DM; Shi J; Liu T; Deng SH; Han R; Xu Y
Cancer Biomark; 2018 Feb; 21(2):355-365. PubMed ID: 29103025
[TBL] [Abstract][Full Text] [Related]
2. SPARCL1 Is a Novel Prognostic Biomarker and Correlates with Tumor Microenvironment in Colorectal Cancer.
Zhang HP; Wu J; Liu ZF; Gao JW; Li SY
Biomed Res Int; 2022; 2022():1398268. PubMed ID: 35111844
[TBL] [Abstract][Full Text] [Related]
3. Down-regulated SPARCL1 is associated with clinical significance in human gastric cancer.
Li P; Qian J; Yu G; Chen Y; Liu K; Li J; Wang J
J Surg Oncol; 2012 Jan; 105(1):31-7. PubMed ID: 22161898
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological significance of reduced SPARCL1 expression in human breast cancer.
Cao F; Wang K; Zhu R; Hu YW; Fang WZ; Ding HZ
Asian Pac J Cancer Prev; 2013; 14(1):195-200. PubMed ID: 23534723
[TBL] [Abstract][Full Text] [Related]
5. SPARCL1 a novel player in cancer biology.
Gagliardi F; Narayanan A; Mortini P
Crit Rev Oncol Hematol; 2017 Jan; 109():63-68. PubMed ID: 28010899
[TBL] [Abstract][Full Text] [Related]
6. Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression.
Hurley PJ; Hughes RM; Simons BW; Huang J; Miller RM; Shinder B; Haffner MC; Esopi D; Kimura Y; Jabbari J; Ross AE; Erho N; Vergara IA; Faraj SF; Davicioni E; Netto GJ; Yegnasubramanian S; An SS; Schaeffer EM
Cancer Res; 2015 Oct; 75(20):4322-34. PubMed ID: 26294211
[TBL] [Abstract][Full Text] [Related]
7. Genomic organization and chromosomal mapping of SPARC-like 1, a gene down regulated in cancers.
Isler SG; Schenk S; Bendik I; Schraml P; Novotna H; Moch H; Sauter G; Ludwig CU
Int J Oncol; 2001 Mar; 18(3):521-6. PubMed ID: 11179481
[TBL] [Abstract][Full Text] [Related]
8. SPARCL1, a Novel Prognostic Predictive Factor for GI Malignancies: a Meta-Analysis.
Hu H; Cai W; Zheng S; Ge W
Cell Physiol Biochem; 2017; 44(4):1485-1496. PubMed ID: 29190626
[TBL] [Abstract][Full Text] [Related]
9. SPARCL1: a potential molecule associated with tumor diagnosis, progression and prognosis of colorectal cancer.
Zhang H; Widegren E; Wang DW; Sun XF
Tumour Biol; 2011 Dec; 32(6):1225-31. PubMed ID: 21887554
[TBL] [Abstract][Full Text] [Related]
10. SPARCL1 is a novel predictor of tumor recurrence and survival in hilar cholangiocarcinoma.
Yu Y; Chen Y; Ma J; Yu X; Yu G; Li Z
Tumour Biol; 2016 Mar; 37(3):4159-67. PubMed ID: 26490986
[TBL] [Abstract][Full Text] [Related]
11. Secreted protein acidic and rich in cysteines-like 1 suppresses aggressiveness and predicts better survival in colorectal cancers.
Hu H; Zhang H; Ge W; Liu X; Loera S; Chu P; Chen H; Peng J; Zhou L; Yu S; Yuan Y; Zhang S; Lai L; Yen Y; Zheng S
Clin Cancer Res; 2012 Oct; 18(19):5438-48. PubMed ID: 22891198
[TBL] [Abstract][Full Text] [Related]
12. SPARCL1 suppresses cell migration and invasion in renal cell carcinoma.
Ye H; Wang WG; Cao J; Hu XC
Mol Med Rep; 2017 Nov; 16(5):7784-7790. PubMed ID: 28944877
[TBL] [Abstract][Full Text] [Related]
13. SPARCL1 suppresses metastasis in prostate cancer.
Xiang Y; Qiu Q; Jiang M; Jin R; Lehmann BD; Strand DW; Jovanovic B; DeGraff DJ; Zheng Y; Yousif DA; Simmons CQ; Case TC; Yi J; Cates JM; Virostko J; He X; Jin X; Hayward SW; Matusik RJ; George AL; Yi Y
Mol Oncol; 2013 Dec; 7(6):1019-30. PubMed ID: 23916135
[TBL] [Abstract][Full Text] [Related]
14. SPARCL1 exhibits different expressions in left- and right-sided colon cancer and is downregulated via DNA methylation.
Hu H; Wu D; Liu X; Yu H; Xu J; Cai W; Huang Y; Bai R; Zhang J; Gu Y; Zheng S; Ge W
Epigenomics; 2021 Aug; 13(16):1269-1282. PubMed ID: 34435512
[TBL] [Abstract][Full Text] [Related]
15. Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome.
Hurley PJ; Marchionni L; Simons BW; Ross AE; Peskoe SB; Miller RM; Erho N; Vergara IA; Ghadessi M; Huang Z; Gurel B; Park BH; Davicioni E; Jenkins RB; Platz EA; Berman DM; Schaeffer EM
Proc Natl Acad Sci U S A; 2012 Sep; 109(37):14977-82. PubMed ID: 22927397
[TBL] [Abstract][Full Text] [Related]
16. Species-, organ- and cell-type-dependent expression of SPARCL1 in human and mouse tissues.
Klingler A; Regensburger D; Tenkerian C; Britzen-Laurent N; Hartmann A; Stürzl M; Naschberger E
PLoS One; 2020; 15(5):e0233422. PubMed ID: 32437418
[TBL] [Abstract][Full Text] [Related]
17. SPARCL1 expression increases with preoperative radiation therapy and predicts better survival in rectal cancer patients.
Kotti A; Holmqvist A; Albertsson M; Sun XF
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1196-202. PubMed ID: 24661672
[TBL] [Abstract][Full Text] [Related]
18. A prospective study on serum secreted protein acidic and rich in cysteine-like 1 as a prognostic marker for severe traumatic brain injury.
Huang HB; Yang SB; Shen LJ; Lv QW; Guo M; Zhou J; Li Z; Yang CS; Wang LY; Zhang H
Clin Chim Acta; 2019 Apr; 491():19-23. PubMed ID: 30639238
[TBL] [Abstract][Full Text] [Related]
19. SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK are prognosis-related in colorectal cancer.
Yu SJ; Yu JK; Ge WT; Hu HG; Yuan Y; Zheng S
World J Gastroenterol; 2011 Apr; 17(15):2028-36. PubMed ID: 21528083
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of
Wang Q; Zheng W
Biomed Res Int; 2021; 2021():6663367. PubMed ID: 33763482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
